Non-small Cell Lung Cancer
Conditions
Keywords
Non-small Cell Lung Cancer, Apatinib, Etoposide
Brief summary
The development of anti-angiogenesis drugs has led to renewed enthusiasm in lung cancer treatments. Apatinib is a tyrosine kinase inhibitor which selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR-2). Etoposide is an oral preparation for lung cancer which is recommended by NCCN guideline. The investigators wondered whether these two drugs have synergistic effects when treating advanced non-small cell lung cancer patients who failed to previous at least 2nd line treatments. Thus, the aim of this trial is to investigate the efficacy and safety of apatinib combined with etoposide in heavily pretreated advanced non-small cell lung cancer.
Interventions
DRUGApatinib
Apatinib, 250mg daily, po, continue until disease progression
DRUGEtoposide
Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
Sponsors
Third Military Medical University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Obtain of informed consent. * Histologically or cytologically confirmed non-small cell lung cancer. * World Health Organization (WHO) performance status (PS) of 0 to 2. * Measurable lesions as defined by RECIST criteria. * Second-line or more treatments. * Wild type of epidermal-growth-factor receptor (EGFR). * Life expectancy ≥12 weeks. * Organ functions normal, as defined below, within two weeks of randomization: • Hb≥90g/L Absolute neutrophils count(ANC)≥1.5×109/L Platelets≥80×109/L Serum bilirubin≤2×ULN; Aspartate transaminase(AST) and alanine transaminase (ALT)≤2.5×ULN(≤5×ULN if liver metastases) Creatinine clearance≥45ml/min or Cr≤1.25×ULN. * Females of child-bearing potential must have negative serum pregnancy test. * Sexually active males and females (of childbearing potential) willing to practice contraception during the study.
Exclusion criteria
* Small cell lung cancer. * Newly diagnosed Central Nervous System (CNS) metastases that have not yet been definitively treated with surgery and/or radiation. * Uncontrolled hypertension. * Myocardial ischemia or infarction more than stage II, cardiac insufficiency. * Abnormal coagulation (INR\>1.5 or PT\>ULN+4, or APTT\>1.5 ULN), bleeding tendency or receiving coagulation therapy. * Difficulties in taking pills (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction). * Hemoptysis, more than 2.5ml daily. * Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis. * Unhealed bone fracture or wound for long time. * Received big surgery, had bone fracture or ulcer in 4 weeks. * Urine protein≥++, or urine protein in 24 hours≥1.0g. * Pregnant or lactating woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | evaluated in 24 months since the treatment began | the first day of treatment to the date that disease progression is reported |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | tumor assessment every 6-8 weeks since the treatment began，up to 24 months | the ratio between the number of responders and number of patients assessable for tumor response |
| Side effects | evaluated in the 24th month since the treatment began according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | — |
| Overall survival | the first day of treatment to death or last survival confirm date,up to 24 months | — |
Countries
China
Contacts
Primary ContactXueqin Yang, PHD
Outcome results
None listed